Jefferies analyst David Steinberg reiterated a Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX) yesterday and set a price target of $50. The company’s shares closed yesterday at $43.
According to TipRanks.com, Steinberg is a 4-star analyst with an average return of 10.7% and a 50.2% success rate. Steinberg covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Supernus Pharmaceuticals, and Menlo Therapeutics Inc.
Pacira Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $49.90, a 16.0% upside from current levels. In a report issued on July 26, H.C. Wainwright also reiterated a Buy rating on the stock with a $48 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $47.55 and a one-year low of $26.95. Currently, Pacira Pharmaceuticals has an average volume of 636.4K.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pacira Pharmaceuticals, Inc. is a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients.
